(Rye Brook, NY – September 13, 2017) –The Leukemia & Lymphoma Society (LLS) today announced the extension of its hurricane relief program set up last week to assist blood cancer patients in Texas and Louisiana affected by Hurricane Harvey, to provide direct support to blood cancer patients hit by Hurricane Irma. The world’s largest non-profit dedicated to fighting blood cancers, LLS committed up to $1 million in direct donations to blood cancer patients. Patients with a confirme...
Rye Brook, NY – September 5, 2017 – In the wake of the destruction caused by Hurricane Harvey, The Leukemia & Lymphoma Society (LLS) announced today that it will donate up to $1 million to help blood cancer patients who have been impacted by the storm. Blood cancer patients living in declared disaster areas impacted by Hurricane Harvey, are eligible to receive $500 to help with cancer-related necessities such as transportation to treatment, lost or damaged medications and other nee...
Rye Brook, N.Y. (September 1, 2017) – The steady march of progress in new treatments for patients with acute myeloid leukemia (AML), one of the most deadly blood cancers which takes more than 10,000 lives in the U.S. each year, continues today with the U.S. Food & Drug Administration approval of gemtuzumab ozogamicin (Mylotarg®). After four decades of little progress for this lethal disease, today’s approval of Mylotarg, manufactured by Pfizer, marks the fourth approval of a thera...
For many people, pets feel like a part of the family. After a cancer diagnosis, pets can offer many benefits. Benefits include: companionship, improved mood, and motivation to stay active. Some hospitals and treatment centers even use animal therapy to help improve patients’ well-being. (Don’t be surprised if you get a visit from a specially trained therapy dog during a chemo infusion!) However, as a cancer patient, there are some things you need to keep in mind when it comes to pets d...
After a cancer diagnosis, your social life will probably change. Cancer can be isolating. You may not feel up for the activities you once enjoyed. This can either be due to feeling poorly physically or emotionally. Side effects may keep you homebound in the days following treatment. Or, your immune system may be so weak that your healthcare team suggests avoiding crowds. Even when you feel well physically, you may be dealing with depression or anxiety. Cancer is a scary, challenging diagnosis...
Coming to a city near you starting Sept 1st! We are lighting it red for YOU as a symbol of our support and in honor of Blood Cancer Awareness Month. Together, we bring light to the darkness of cancer. Join us by looking for a participating location near you (list below) that’s turning it red for Blood Cancer Awareness Month, SHARE your photo with #FightBloodCancer and you may win a fun prize!
August 30 commemorated a new era in cancer treatment with the U.S. Food and Drug Administration (FDA) approval of a new, cutting-edge gene therapy that reprograms a patient’s immune system to find and kill cancer cells. This highly personalized therapy known as Kymriah (previously CTL019 or tisagenlecleucel-T) signifies the promise of CAR (chimeric antigen receptor) T-cell immunotherapy, an approach that The Leukemia & Lymphoma Society (LLS) recognized early on held great promise f...
Dear Parents, LLS is collaborating with researchers at the Kennedy Krieger Institute and Johns Hopkins who are interested in learning more about the experiences and challenges of childhood cancer survivors and their caregivers related to the transition back to school after a diagnosis of cancer. According to our records, you have a school-aged or older child who has been treated for cancer and has returned to a formal school setting. We would appreciate your help by your participation in t...
In this Ask the Expert segment, a Patient Power community member wants to know if and why a bone marrow biopsy is necessary if her ET diagnosis has been confirmed by blood work. Dr. Srdan Verstovsek responds.
What are high-risk CLL chromosomal abnormalities, and how could they impact treatment? Listen as Drs. Susan Leclair and William Wierda explain.
